title: Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
authors.forename: Andrea
authors.initials: A
authors.lastname: Calcagno
authors.forename: Silvia
authors.initials: S
authors.lastname: Nozza
authors.forename: Daniel
authors.initials: D
authors.lastname: Gonzalez de Requena
authors.forename: Andrea
authors.initials: A
authors.lastname: Galli
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Avolio
authors.forename: Marco
authors.initials: M
authors.lastname: Simiele
authors.forename: Stefania
authors.initials: S
authors.lastname: Chiappetta
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonora
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004359:Drug Therapy, Combination / Q000379:methods; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage; D008297:Male; D000077592:Maraviroc; D010949:Plasma / Q000737:chemistry; D019438:Ritonavir / Q000008:administration & dosage; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D061466:Lopinavir; D000077592:Maraviroc; D019438:Ritonavir
keywords: NRTI-sparing; PK; antivirals